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THE ROLE OF PRIMARY PCI FOR ST-SEGMENT ELE-
VATION MYOCARDIAL INFARCTION
The guidelines of the American College of Cardiology and
American Heart Association state that primary PCI is a class
I indication in patients with ST-segment elevation myocardial
infarction who can undergo the invasive procedure within 12
h after the onset of symptoms. This is true provided that the
procedure is performed timely by experienced cardiologists in
an appropriate facility.
Reperfusion treatment is the therapy indicated for patients with
myocardial infarction associated with ST-segment elevation
(greater than 0.1 mV in at least two contiguous electrocardio-
graphic leads). Primary PCI is to be preferred if skilled inter-
ventional cardiologists and a catheterisation laboratory with sur-
gical facilities are available and if the procedure may be per-
formed within 90 min after the first clinical contact with the
patient. Primary PCI should also be preferred for selected
patients even if the period between the first clinical contact and
the invasive procedure (“door-to-balloon” interval) is longer than
90 min. These selected patients include those with an elevated
risk of bleeding with fibrinolytic therapy (including people 75
years of age or older), subjects with a contraindication to fibri-
nolytic therapy, individuals whose clinical findings (including
hypotension and tachycardia) indicate a high risk of a compli-
cated medical course or death, and patients with cardiogenic
shock. The guidelines of the American College of Cardiology
and American Heart Association state that primary PCI is a class
I indication in patients with ST-segment elevation myocardial
infarction who can undergo the procedure within 12 h after the
onset of symptoms, provided that the invasive procedure is per-
formed timely by experienced cardiologists in an appropriate
facility. Experienced operators are those who perform more than
75 interventional procedures each year in a cath lab in which
more than 200 coronary interventional procedures are performed
each year (and at least 36 of them must be primary procedures),
and that includes a cardiac surgical facility. The European
Society of Cardiology also considers primary PCI to be the pre-
ferred myocardial reperfusion approach in patients with myocar-
dial infarction with ST-segment elevation (class I indication).
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EFFICACY OF A SELF-REGULATION PROGRAMME
BASED ON DAILY WEIGHING AND ON FACE-TO-FACE
INTERVENTION IN MAINTAINING WEIGHT LOSS
THROUGH TIME
Body weight self-regulation programmes, particularly with a
face-to-face intervention performed by educators, allow the
maintenance over time of previous weight loss better than pro-
grammes based only on periodical written advice.
One of the major challenges for individuals who succeeded in
losing weight is that of maintaining the body weight achieved.
The Authors of this study set up two programmes for the main-
tenance of body weight based on the self-regulation theory (one
with personal contact with educators, the other with Internet-
based interventions) and compared them with a control group
receiving quarterly newsletters. 314 subjects, who had lost a
mean weight of 19.3 kg in the two years before, were assigned
to three groups; the content of the two educational programmes
based on self-regulation was the same. In the course of the 18
months of the study, the subjects assigned to the self-regulation
programme that included a face-to-face intervention gained a
mean of 2.5 kg of body weight, while the participants in the self-
regulation programme with Internet-based interventions gained
4.7 kg, and the control group 4.9 kg. The proportion of partici-
pants who regained 2.3 kg in the 18 months of the study was sig-
nificantly lower in the intervention group with face-to-face inter-
vention (45.7%) if compared to the Internet-based intervention
group (54.8%) and to the control group (72.4%). Daily self-
weighing was more frequent in the two intervention groups if
compared to the control group. Therefore, maintenance through
time of weight loss is favoured in a very significant way if face-
to-face self-regulation programmes are adopted, instead of the
usual programmes based on periodical written advice.
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LIMITED UTILITY OF ATYPICAL ANTIPSYCHOTIC
DRUGS IN THE TREATMENT OF PATIENTS AFFECTED
BY ALZHEIMER’S DISEASE IN THE REAL-WORLD
In this real-world controlled randomised trial significant clin-
ical improvements with the use of atypical antipsychotic drugs
were not recorded, and therefore the Authors concluded that
the side effects of these drugs offset the benefits of drug ther-
apy for psychosis and agitation in subjects with Alzheimer’s
disease.
Traditional clinical studies are not often able to reproduce the
conditions in which clinical practice is daily implemented,
namely, the real setting in which patients and their diseases vary
over time. Moreover, the dosage of administered drugs is not
infrequently modified on account of their side effects. In order to
reproduce in the most authentic way real-world conditions, a
group of US researchers designed and conducted a pragmatic
study to understand if atypical second-generation antipsychotic
drugs are useful in daily clinical practice so as to control behav-
iour disorders of people affected by Alzheimer’s disease. These
drugs are commonly used to treat psychosis and agitation in sub-
jects with Alzheimer’s disease, even though their benefits are
uncertain and concerns about their safety have recently emerged.
This double-blind, placebo-controlled clinical study, which
enrolled patients in 42 different centres, recruited 421 individu-
als with Alzheimer’s disease and psychosis or agitation. The
patients were assigned in a randomised way to treatment with
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olanzepine (mean dose: 5.5 mg daily), quetiapine (mean dose:
56.5 mg daily), risperidone (mean dose: 1 mg daily) or placebo,
and followed up to 36 weeks. No significant differences have
emerged among the different treatments and placebo with regard
to the time to the discontinuation of the therapy (olanzepine:
median time 8.1 weeks; quetiapine: median time 5.3 weeks;
risperidone: median time 7.4 weeks; placebo: median time 8
weeks), and approximately half the patients discontinued drug
assumption in the time span of 8 weeks. No significant differ-
ence was recorded among the studied drugs and the placebo with
reference to the improvements of the patients recorded by means
of the Clinical Global Impression of Change scale at 12 weeks.
The Authors of this study conclude that, overall, the adverse
effects of studied drugs offset the benefits of the therapy with
atypical antipsychotic drugs in the treatment of psychosis and
agitation in patients with Alzheimer’s disease.
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D-DIMER DOSAGE ALLOWS THE IDENTIFICATION OF
PATIENTS IN WHOM ANTICOAGULATION THERAPY
SHOULD BE CONTINUED FOR A LONGER PERIOD OF TIME
Individuals who have suffered an idiopathic proximal deep-
vein thrombosis or pulmonary embolism and who have an
abnormal D-Dimer value one month after the discontinuation
of anticoagulation therapy have an incidence of recurrent
venous thromboembolism significantly higher than patients
with D-Dimer normal values.
A group of Italian researchers designed and conducted a multi-
centre clinical trial in patients with a first unprovoked proximal
deep-vein thrombosis or pulmonary embolism who had received a
vitamin K antagonist for at least three months. In the enrolled sub-
jects D-Dimer was measured one month after the discontinuation
of the anticoagulation therapy. In patients with normal D-Dimer
values anticoagulation therapy was not continued, while individu-
als with abnormal D-Dimer values were subdivided in two groups:
in one group anticoagulation therapy was discontinued, while in
the other this therapy was prolonged for a mean of 1.4 years. In
the 223 patients (37%) in whom D-Dimer values were abnormal,
those in whom anticoagulation therapy was discontinued had an
incidence of venous thromboembolism clearly higher (15%) as
compared to those in whom anticoagulation therapy was not dis-
continued (2.9%). Overall, the patients in whom the anticoagula-
tion therapy was discontinued were four times more likely to
undergo a thromboembolic recurrence (adjusted hazard ratio:
4.26, 95% confidence interval 1.23–14.6; p=0.02) than subjects in
whom anticoagulation therapy was prolonged. Therefore, in
patients with previous venous thromboembolism and abnormal D-
Dimer values, anticoagulation should be continued for a longer
period of time as compared to patients with idiopathic venous
thromboembolism and normal D-Dimer values.
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